Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
03696 英矽智能
INSILICO
Listing Date2025/12/30    Listing Tomorrow
Listing Price24.050
Grey Market Performance
Last updated: 29/12/2025 19:59  Refresh
  • Bright Smart
    up 36.400 +12.350 (+51.351%)
    High
    46.000
     
    Low
    31.200
    Volume
    280,000
    One Lot Profit
    +6,175.00
  • Phillip
    up 36.100 +12.050 (+50.104%)
    High
    72.300
     
    Low
    31.000
    Volume
    3,560,000
    One Lot Profit
    +6,025.00
  • Futu
    up 36.860 +12.810 (+53.264%)
    High
    45.500
     
    Low
    33.020
    Volume
    4,175,000
    One Lot Profit
    +6,405.00
  • Bid
  • Ask
  • 36.380
  • (1) 500
  • 500 (1)
  • 36.400
  • 36.360
  • (1) 500
  • 0 (0)
  • 36.420
  • 36.340
  • (0) 0
  • 0 (0)
  • 36.440
  • 36.320
  • (0) 0
  • 0 (0)
  • 36.460
  • 36.300
  • (0) 0
  • 0 (0)
  • 36.480
  • 36.280
  • (0) 0
  • 1.5K (3)
  • 36.500
  • 36.260
  • (1) 1K
  • 0 (0)
  • 36.520
  • 36.240
  • (0) 0
  • 0 (0)
  • 36.540
  • 36.220
  • (0) 0
  • 0 (0)
  • 36.560
  • 36.200
  • (0) 0
  • 0 (0)
  • 36.580
  • Bid
  • Ask
  • 36.060
  • (1) 6K
  • 500 (1)
  • 36.100
  •  
  • (0) 0
  • 0 (0)
  •  
  •  
  • (0) 0
  • 0 (0)
  •  
  •  
  • (1) 4.5K
  • 0 (0)
  •  
  •  
  • (0) 0
  • 0 (0)
  •  
 
Hide
COMPANY PROFILE

InSilico Medicine Cayman TopCo was founded in 2014, it is a reputable and global AI-driven drug discovery and development company. The Group operates under a project-based business model, deriving revenue primarily from out-licensing and collaboration arrangements.

--

As of December 10, 2025, the Group has generated more than 20 clinical or IND-enabling stage assets using Pharma.AI, its proprietary generative AI platform, with three of these assets out-licensed to international pharmaceutical and healthcare companies with the maximum total contract value of US$2.1 billion, and one Phase II asset under self development.

--

Leveraging Pharma.AI, on average, the Group’s drug candidates progress from target discovery to pre-clinical candidate (PCC) confirmation within 12-18 months, significantly shorter than the average of 4.5 years required by traditional methods. Pharma.AI consisting of Biology42, Chemistry42, Medicine42, and Science42, designed to operate across the entire drug discovery and development continuum.

--

The Group’s business model consists of drug discovery and pipeline development, software solutions and other discovery related to non-pharma sectors. The Group conduct its business under the brand name “InSilico Medicine” and “英矽智能” and its major customers are pharmaceutical/biotech companies.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureSoftware & Services
Major Business AreaGlobal
Board Lot500
GLOBAL OFFERING
No. of Offer Shares94.69M shares
No. of International Offer Shares85.22M shares
No. of HK Offer Shares9.47M shares
Offer Price$24.05
Stock Code3696
Sponsor(s)Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, GF Capital (Hong Kong) Limited
Underwriter(s)Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, GF Securities (Hong Kong) Brokerage Limited, BNP Paribas Securities (Asia) Limited, Sinolink Securities (Hong Kong) Company Limited, BOCI Asia Limited
TIME TABLE
Application PeriodDec 18 (Thu) - noon, Dec 23 (Tue)
Price Determination Date--
Result Announcement DateOn or before Dec 29 (Mon)
Result Announcement DateOn or before Dec 29 (Mon)
Result Announcement DateOn or before Dec 30 (Tue)
Dealings in Shares commence onDec 30, 2025. (Tue)
Reallocation of Shares Offered
Sales Statistics (HKD)
Offer Price$24.05
Capitalization13.41B
NAV / share ($)$-18.41 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 24.05, the net proceeds raised would be HKD 2.03B, of which
48% : Clinical research and development of key clinical stage pipeline drug candidates
15% : Development of new generative AI models and the associated validation research work
12% : Development and expansion of automated lab
20% : For early-stage drug discovery and development
5% : Working capital
IPO NEWS
29/12/2025 18:35
{New Stock}INSILICO ends up 50.1% at HK$36.1 on grey market
29/12/2025 16:20
{New Stock}INSILICO(03696) up 66.32% at HK$40 on grey market
Related Document
Prospectus Prospectus  Chinese VersionProspectus  English Version
Remark： The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
 :
Subscribing Lot :
Subscribing Fee :
Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.